AIDS Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV/AIDS
Studies from Complutense University provide new data on HIV/AIDS
June 15th, 2009
According to recent research published in the journal Antiviral Therapy, "Risk factors for loss of virological response in patients receiving lopinavir/ritonavir (LPV/r) monotherapy as maintenance treatment have not been determined. In 121 patients enrolled in the OK and OK04 clinical trials assigned to receive monotherapy with LPV/r, we attempted to identify factors associated with loss of virological suppression at 48 weeks, defined as confirmed serum HIV type-1 RNA >50 copies/ml, with missing data or changes caused by toxicity censored." "Univariate and multivariate Cox proportional hazard models were used to calculate hazard ratios for the risk of loss of...
Source: AIDS Weekly (2009-06-15)
|
